Loading
The 2022 five-year report of PRODIGE 24 confirming that modified FOLFIRINOX after pancreatic cancer surgery gives a median survival of about four and a half years against three with gemcitabine, and that 43 percent of patients were alive at five years.
The mature analysis of the PRODIGE 24/Canadian Cancer Trials Group PA6 trial, 493 patients aged 18 to 79 randomised at 77 hospitals in France and Canada between April 2012 and October 2016 within 3 to 12 weeks of R0 or R1 resection to 24 weeks of modified FOLFIRINOX or gemcitabine; data cutoff June 2021, median follow-up 69.7 months. Median disease-free survival was 21.4 versus 12.8 months (hazard ratio 0.66) and five-year disease-free survival 26.1 versus 19.0 percent; median overall survival was 53.5 versus 35.5 months (hazard ratio 0.68, 95 percent confidence interval 0.54 to 0.85, P = 0.001) and five-year overall survival 43.2 versus 31.4 percent; median metastasis-free survival 29.4 versus 17.7 months (hazard ratio 0.64) and cancer-specific survival 54.7 versus 36.3 months (hazard ratio 0.65). Multivariable analysis identified modified FOLFIRINOX, age, tumour grade, staging and larger-volume centre as favourable prognostic factors.
The best survival ever recorded in a pancreatic cancer trial, and the benchmark every perioperative trial (PREOPANC-3, Alliance A021806) and every adjuvant RAS inhibitor or vaccine trial (RASolute 304, IMCODE003) now has to beat or add to.
Shares Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial, Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed, Neoadjuvant / adjuvant / perioperative, Resectable pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Thierry Conroy, PRODIGE 24 / CCTG PA6, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Neoadjuvant / adjuvant / perioperative, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Cytotoxic chemotherapy and the tag pancreatic-evidence.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-evidence.
Shares A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC, FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question and the tag pancreatic-evidence.
Shares Hazard ratio (HR), Overall survival (OS), Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Cytotoxic chemotherapy and the tag pancreatic-evidence.
Shares Hazard ratio (HR), Overall survival (OS), Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question and the tag pancreatic-evidence.
Shares Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC), FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question and the tag pancreatic-evidence.